Zahra Ali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zahra Ali has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Sina Mohagheghi
Department of Clinical Biochemistry, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
3 shared publications - Amir Mohammad Zargar
Department of Clinical Biochemistry, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan 6517838736, Iran
2 shared publications Erfan Golestannejad
Department of Clinical Biochemistry, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
1 shared publication- Shayan Marhamati
Department of Clinical Biochemistry, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
1 shared publication Zahra Ali
Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran - Student Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran
1 shared publication
Latest Publications
- Open Access
- 31 October 2025
- Published by Maad Rayan Publishing Company in Avicenna Journal of Medical Biochemistry
- Vol. 13 (1) , 36-41
Oxidative Stress in Fatty Liver Disease with Metabolic and Non-metabolic Etiologies
Background: Fatty liver disease (FLD) is classified into metabolic dysfunction-associated fatty liver disease (MAFLD) and non-MAFLD based on the presence of metabolic abnormalities. The pathophysiology of FLD is complex; however, oxidative stress (OS) seems to play a significant role in its progression. Objectives: This study examined oxidative stress markers linked to FLD. Methods: A total of 64 patients with FLD, including 38 MAFLD and 26 non-MAFLD patients, respectively, were evaluated and compared with 22 healthy individuals. To assess oxidative stress, in addition to the activities of catalase (CAT), glutathione peroxidase (GPx), and superoxide dismutase (SOD) enzymes, total oxidant status (TOS), malondialdehyde (MDA), and total antioxidant capacity (TAC) were measured in the serum of the participants. Results: It was found that TOS, MDA, and TAC levels in the serum were significantly higher in the FLD group compared to the healthy individuals. Notably, these increases were more pronounced in the MAFLD group compared to the non-MAFLD group. Additionally, CAT and GPx enzyme activities were significantly elevated in patients with FLD than in the control group. The MAFLD group exhibited the highest CAT enzyme activity, while the non-MAFLD group demonstrated the highest GPx enzyme activity. Conversely, serum SOD enzyme activity was decreased across all studied groups, with no significant differences observed between them. Conclusion: Patients with MAFLD and non-MAFLD exhibit an imbalance in their oxidative stress systems. It appears that CAT and GPx enzymes probably play crucial roles in the antioxidant defense mechanisms in these patients, respectively.
- 31 October 2025
- Published by Maad Rayan Publishing Company in Avicenna Journal of Medical Biochemistry
- Vol. 13 (1) , 36-41
Open AccessOxidative Stress in Fatty Liver Disease with Metabolic and Non-metabolic Etiologies
Background: Fatty liver disease (FLD) is classified into metabolic dysfunction-associated fatty liver disease (MAFLD) and non-MAFLD based on the presence of metabolic abnormalities. The pathophysiology of FLD is complex; however, oxidative stress (OS) seems to play a significant role in its progression. Objectives: This study examined oxidative stress markers linked to FLD. Methods: A total of 64 patients with FLD, including 38 MAFLD and 26 non-MAFLD patients, respectively, were evaluated and compared with 22 healthy individuals. To assess oxidative stress, in addition to the activities of catalase (CAT), glutathione peroxidase (GPx), and superoxide dismutase (SOD) enzymes, total oxidant status (TOS), malondialdehyde (MDA), and total antioxidant capacity (TAC) were measured in the serum of the participants. Results: It was found that TOS, MDA, and TAC levels in the serum were significantly higher in the FLD group compared to the healthy individuals. Notably, these increases were more pronounced in the MAFLD group compared to the non-MAFLD group. Additionally, CAT and GPx enzyme activities were significantly elevated in patients with FLD than in the control group. The MAFLD group exhibited the highest CAT enzyme activity, while the non-MAFLD group demonstrated the highest GPx enzyme activity. Conversely, serum SOD enzyme activity was decreased across all studied groups, with no significant differences observed between them. Conclusion: Patients with MAFLD and non-MAFLD exhibit an imbalance in their oxidative stress systems. It appears that CAT and GPx enzymes probably play crucial roles in the antioxidant defense mechanisms in these patients, respectively.
- 30 June 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-12
Investigating the expression of CD180, LY96, VCAM-1, and CSF2RB in the lipopolysaccharide response pathway across different liver cirrhosis etiologies
Background Liver cirrhosis represents a significant global health burden with diverse etiological factors. The lipopolysaccharide response pathway is critical in liver disease development. This study investigates this pathway in liver cirrhosis associated with various etiologies, including nonalcoholic steatohepatitis, alcohol consumption, viral infections, autoimmune disorders, and cholestatic disorders. Methods and results The GSE25097 and GSE54238 microarray datasets were retrieved from the Gene Expression Omnibus (GEO) database using R software. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed on the overlapping Differentially Expressed Genes (DEGs). Gene expression was determined by RT-qPCR, and protein expression was determined by Western blot. A total of 499 overlapping DEGs were identified between the two datasets. Then, the GOBP enrichment analysis subsequently discovered the lipopolysaccharide response pathway, highlighting genes such as CD180, LY96, VCAM-1, and CSF2RB. Based on bioinformatics analysis, the expressions of all mentioned genes were elevated in cirrhotic samples. However, experimental results showed an increase only in CD180 gene expression. Our research has shown that the expressions of the LY96, VCAM-1, and CSF2RB genes were elevated only in PSC cirrhosis. The PSC group had an elevation in LY96 protein expression. On the other hand, all the gene expressions significantly decreased in NASH cirrhosis, although only the VCAM-1 protein expression was reduced in NASH cirrhosis. Conclusions The response to the lipopolysaccharide pathway has a complicated role in liver disease pathogenesis. While gene expression of pathway components increases in cholangitis-related cirrhosis, it decreases in NASH-associated cirrhosis.
- 30 June 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-12
Investigating the expression of CD180, LY96, VCAM-1, and CSF2RB in the lipopolysaccharide response pathway across different liver cirrhosis etiologies
Background Liver cirrhosis represents a significant global health burden with diverse etiological factors. The lipopolysaccharide response pathway is critical in liver disease development. This study investigates this pathway in liver cirrhosis associated with various etiologies, including nonalcoholic steatohepatitis, alcohol consumption, viral infections, autoimmune disorders, and cholestatic disorders. Methods and results The GSE25097 and GSE54238 microarray datasets were retrieved from the Gene Expression Omnibus (GEO) database using R software. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed on the overlapping Differentially Expressed Genes (DEGs). Gene expression was determined by RT-qPCR, and protein expression was determined by Western blot. A total of 499 overlapping DEGs were identified between the two datasets. Then, the GOBP enrichment analysis subsequently discovered the lipopolysaccharide response pathway, highlighting genes such as CD180, LY96, VCAM-1, and CSF2RB. Based on bioinformatics analysis, the expressions of all mentioned genes were elevated in cirrhotic samples. However, experimental results showed an increase only in CD180 gene expression. Our research has shown that the expressions of the LY96, VCAM-1, and CSF2RB genes were elevated only in PSC cirrhosis. The PSC group had an elevation in LY96 protein expression. On the other hand, all the gene expressions significantly decreased in NASH cirrhosis, although only the VCAM-1 protein expression was reduced in NASH cirrhosis. Conclusions The response to the lipopolysaccharide pathway has a complicated role in liver disease pathogenesis. While gene expression of pathway components increases in cholangitis-related cirrhosis, it decreases in NASH-associated cirrhosis.
- Open Access
- 6 February 2025
- Published by DoNotEdit
- Vol. 31 (4) , 197-205
Opposing Expressions of Nidogen-1 and Cdc42 Genes in the Development of Liver Cirrhosis in Patients with Non-Alcoholic Fatty Liver Disease
Background and Objective: The roles of Nidogen-1 and Cdc42 genes as significant factors in the metabolism of the extracellular matrix have been demonstrated in the fibrosis of various tissues. This study investigates the gene expressions of Nidogen-1 and Cdc42 in the liver tissue of patients with cirrhosis, as well as in patients with simple non-alcoholic steatosis and control subjects. Materials and Methods: In this case-control study, 38 tissue samples were collected and analyzed across three groups: cirrhosis (24 samples), simple steatosis (6 samples), and the control group (8 samples). The expression of Nidogen-1 and Cdc42 genes was investigated using RT-qPCR. Results: The gene expressions of Nidogen-1 and Cdc42 in tissues affected by cirrhosis were significantly lower compared to the control group (P=0.001 and P=0.008, respectively). The Nidogen-1 gene exhibited the lowest expression in tissues with Nonalcoholic steatohepatitis (NASH) cirrhosis when compared to the control group, while its expression in tissues with simple steatosis fell between that of the NASH cirrhosis and control groups. Conversely, the expression of the Cdc42 gene in tissues with simple steatosis was significantly lower than in liver tissues with NASH cirrhosis (P=0.043). Conclusion: The gene expressions of Nidogen-1 and Cdc42 decrease in cirrhosis; however, they exhibit different levels between steatosis and NASH cirrhosis. Therefore, the anti-fibrotic role of Nidogen-1 and the involvement of Cdc42 in fibrosis formation are plausible
- 6 February 2025
- Published by DoNotEdit
- Vol. 31 (4) , 197-205
Open AccessOpposing Expressions of Nidogen-1 and Cdc42 Genes in the Development of Liver Cirrhosis in Patients with Non-Alcoholic Fatty Liver Disease
Background and Objective: The roles of Nidogen-1 and Cdc42 genes as significant factors in the metabolism of the extracellular matrix have been demonstrated in the fibrosis of various tissues. This study investigates the gene expressions of Nidogen-1 and Cdc42 in the liver tissue of patients with cirrhosis, as well as in patients with simple non-alcoholic steatosis and control subjects. Materials and Methods: In this case-control study, 38 tissue samples were collected and analyzed across three groups: cirrhosis (24 samples), simple steatosis (6 samples), and the control group (8 samples). The expression of Nidogen-1 and Cdc42 genes was investigated using RT-qPCR. Results: The gene expressions of Nidogen-1 and Cdc42 in tissues affected by cirrhosis were significantly lower compared to the control group (P=0.001 and P=0.008, respectively). The Nidogen-1 gene exhibited the lowest expression in tissues with Nonalcoholic steatohepatitis (NASH) cirrhosis when compared to the control group, while its expression in tissues with simple steatosis fell between that of the NASH cirrhosis and control groups. Conversely, the expression of the Cdc42 gene in tissues with simple steatosis was significantly lower than in liver tissues with NASH cirrhosis (P=0.043). Conclusion: The gene expressions of Nidogen-1 and Cdc42 decrease in cirrhosis; however, they exhibit different levels between steatosis and NASH cirrhosis. Therefore, the anti-fibrotic role of Nidogen-1 and the involvement of Cdc42 in fibrosis formation are plausible